norgestimate has been researched along with Venous Thromboembolism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Del Savio, MC; Facchinetti, F; Grandi, G | 1 |
| Curtis, KM; Dragoman, MV; Gaffield, ME; Tepper, NK | 1 |
2 review(s) available for norgestimate and Venous Thromboembolism
| Article | Year |
|---|---|
The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism.
Topics: Animals; Contraceptive Agents, Hormonal; Female; Humans; Levonorgestrel; Norgestrel; Risk; Venous Thromboembolism | 2021 |
Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.
Topics: Administration, Cutaneous; Adolescent; Adult; Contraceptive Devices, Female; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Estrogens; Female; Humans; Levonorgestrel; Norgestrel; Progestins; Risk Factors; Thromboembolism; Venous Thromboembolism; Young Adult | 2017 |